article Open Access

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

BMC Cancer · 2010 · Vol. 10(1) · pp. 529–529

Li Jin✉(Fudan University Shanghai Cancer Center)Xinmin Zhao(Fudan University Shanghai Cancer Center)Lei Chen(Fudan University Shanghai Cancer Center)Haiyi Guo(Fudan University Shanghai Cancer Center)Fangfang Lv(Shanghai Medical College of Fudan University)Jia Ka(Shanghai Medical College of Fudan University)Ke Yv(Chinese Academy of Sciences)Feng‐Qing Wang(Shanghai Institute of Materia Medica)Chuan Li(Chinese Academy of Sciences)Jun Qian(Fudan University Shanghai Cancer Center)Chunlei Zheng(Fudan University Shanghai Cancer Center)Yunxia Zuo(Fudan University Shanghai Cancer Center)

View via DOI Full-text PDF

Abstract

ClinicalTrials.gov unique identifier: NCT00633490.

Angiogenesis and VEGF in Cancer Cancer Treatment and Pharmacology Colorectal Cancer Treatments and StudiesApatinibMedicinePharmacokineticsAdverse effectInternal medicinePharmacologyVascular endothelial growth factorGastroenterologyChemotherapyVEGF receptors

MeSH terms

AdultAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsPyridinesTomography, X-Ray ComputedTreatment OutcomeMaximum Tolerated DoseVascular Endothelial Growth Factor Receptor-2

Citations

274

FWCI

1.62

field-weighted impact

References

Percentile

82%

vs. same field & year

Citations per year

References

Vascular Endothelial Growth Factor: Basic Science and Clinical Progress